SCHEMBL2435898

SCHEMBL2435898

c1ccc(CN(Cc2ccc3nc(-c4ccc(-c5cc[nH]n5)cc4)cn3c2)Cc2ccccn2)nc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A3 P47895 5/20 0.39
ALDH1A1 P00352 4/20 0.39
ALDH1A2 O94788 1/20 0.39
APP P05067 2/20 0.38
CXCR4 P61073 4/20 0.38
SMN1; SMN2 Q16637 3/20 0.36
MAPT P10636 1/20 0.36
LIN28A Q9H9Z2 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
SLC2A1 P11166 1/20 0.36
HRH3 Q9Y5N1 3/20 0.36
NPC1 O15118 3/20 0.35
RAB9A P51151 3/20 0.35
PKM P14618 2/20 0.35
MAPK1 P28482 1/20 0.35
KDM4E B2RXH2 1/20 0.35
TP53 P04637 1/20 0.35
HPGD P15428 1/20 0.35
TSHR P16473 1/20 0.35
CDK5 Q00535 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2425575 0.77 ALDH1A1 (0.39) ALDH1A3ALDH1A1ALDH1A2APPSMN1; SMN2
SCHEMBL12291868 0.70 APP (0.36) ALDH1A3ALDH1A1APPSMN1; SMN2HRH3
SCHEMBL2427073 0.70 RAB9A (0.63) ALDH1A3ALDH1A1ALDH1A2SMN1; SMN2MAPT
SCHEMBL2430718 0.69 APP (0.59) ALDH1A3ALDH1A1ALDH1A2APPSMN1; SMN2
SCHEMBL2430633 0.69 APP (0.59) ALDH1A3ALDH1A1ALDH1A2APPSMN1; SMN2
SCHEMBL21211528 0.67 TDP1 (0.70) APPCXCR4SMN1; SMN2MAPTLIN28A
SCHEMBL30191149 0.66 SMN1; SMN2 (0.79) ALDH1A1APPCXCR4SMN1; SMN2MAPT
SCHEMBL138261 0.64 SMN1; SMN2 (0.83) ALDH1A1APPCXCR4SMN1; SMN2MAPT
SCHEMBL18211842 0.64 NPSR1 (0.63) ALDH1A1APPCXCR4SMN1; SMN2MAPT
SCHEMBL30359538 0.63 TDP1 (0.63) ALDH1A1APPCXCR4SMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1956013-B1 DIAGNOSTIC AND REMEDY FOR DISEASE CAUSED BY AMYLOID AGGREGATION AND/OR DEPOSITION FUJIFILM RI PHARMA CO LTD (JP) 2016-04-13 EP disclosed
EP-1956013-B1 DIAGNOSTIC AND REMEDY FOR DISEASE CAUSED BY AMYLOID AGGREGATION AND/OR DEPOSITION FUJIFILM RI PHARMA CO LTD (JP) 2016-04-13 EP disclosed
US-8022075-B2 Diagnostic and remedy for disease caused by amyloid aggregation and/or deposition FUJIFILM RI PHARMA CO., LTD. (JP) 2011-09-20 US disclosed
US-8022075-B2 Diagnostic and remedy for disease caused by amyloid aggregation and/or deposition FUJIFILM RI PHARMA CO., LTD. (JP) 2011-09-20 US disclosed
US-8022075-B2 Diagnostic and remedy for disease caused by amyloid aggregation and/or deposition FUJIFILM RI PHARMA CO., LTD. (JP) 2011-09-20 US disclosed
US-20090162283-A1 DIAGNOSTIC AND REMEDY FOR DISEASE CAUSED BY AMYLOID AGGREGATION AND/OR DEPOSITION FUJIFILM RI PHARMA CO., LTD. (JP) 2009-06-25 US disclosed
US-20090162283-A1 DIAGNOSTIC AND REMEDY FOR DISEASE CAUSED BY AMYLOID AGGREGATION AND/OR DEPOSITION FUJIFILM RI PHARMA CO., LTD. (JP) 2009-06-25 US disclosed
EP-1956013-A1 DIAGNOSTIC AND REMEDY FOR DISEASE CAUSED BY AMYLOID AGGREGATION AND/OR DEPOSITION Fujifilm RI Pharma Co., Ltd. (JP) 2008-08-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090162283-A1 DIAGNOSTIC AND REMEDY FOR DISEASE CAUSED BY AMYLOID AGGREGATION AND/OR DEPOSITION APP, TTR, BACE1 ALDH1A3 3748/4885ALDH1A1 2231/4885ALDH1A2 2954/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.